Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 7/20 | 0.69 |
| ▸ | LMNA | P02545 | 5/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.56 |
| ▸ | HTT | P42858 | 3/20 | 0.56 |
| ▸ | TSHR | P16473 | 4/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 4/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | TP53 | P04637 | 2/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3209230 | 0.88 | HSD11B1 (0.57) | HSD11B1LMNASMN1; SMN2HTTTSHR | |
| SCHEMBL3207442 | 0.85 | LMNA (0.74) | HSD11B1LMNASMN1; SMN2HTTTSHR | |
| SCHEMBL3215041 | 0.85 | PKM (0.65) | HSD11B1LMNASMN1; SMN2HTTTSHR | |
| SCHEMBL3214231 | 0.82 | HSD11B1 (1.00) | HSD11B1LMNASMN1; SMN2HTTMEN1 | |
| SCHEMBL3205817 | 0.81 | HSD11B1 (0.76) | HSD11B1LMNATSHRMAPK1MEN1 | |
| SCHEMBL3221923 | 0.81 | ALDH1A1 (0.52) | HSD11B1LMNASMN1; SMN2HTTTSHR | |
| SCHEMBL4486893 | 0.78 | HSD11B1 (1.00) | HSD11B1LMNASMN1; SMN2HTTMEN1 | |
| SCHEMBL3219644 | 0.74 | MAPK1 (0.60) | HSD11B1LMNASMN1; SMN2HTTTSHR | |
| SCHEMBL3222472 | 0.74 | HSD11B1 (0.73) | HSD11B1LMNASMN1; SMN2HTTMEN1 | |
| SCHEMBL19255971 | 0.74 | HSD11B1 (1.00) | HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100029648-A1 | 11-Beta HSD1 Inhibitors | XIANG JASON SHAOYUN | 2010-02-04 | — | — | US | disclosed |
| US-7632838-B2 | 11-beta HSD1 inhibitors | WYETH (US) | 2009-12-15 | — | — | US | disclosed |
| US-20070219198-A1 | 11-Beta HSD 1 inhibitors | WYETH (US) | 2007-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029648-A1 | 11-Beta HSD1 Inhibitors | HSD11B1, HSD3B1, HSD11B2 | HSD11B1 1/4885LMNA 3748/4885SMN1; SMN2 3575/4885 |
| US-20070219198-A1 | 11-Beta HSD 1 inhibitors | HSD11B1, HSD11B2, HSD3B1 | HSD11B1 1/4885LMNA 3681/4885SMN1; SMN2 3686/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.